(RTTNews) - Eli Lilly and Company (LLY) reported that Foundayo 17.2 mg was associated with greater weight loss and better blood sugar control than oral semaglutide 25 mg in adults with type 2 diabetes, based on a new indirect treatment comparison.
(RTTNews) - Tuesday, Eli Lilly (LLY) said Foundayo 17.2 mg showed greater weight loss and A1C reductions than oral semaglutide 25 mg in an indirect treatment comparison involving adults with type 2 diabetes.
(RTTNews) - Novo Nordisk A/S (NVO) and Jiangsu Hengrui Pharmaceuticals Co., Ltd. (1276.HK) announced Tuesday that they have entered into an exclusive license agreement for HRS-1596, a Phase 1-ready GLP-1/GIP dual receptor agonist with potential for once-weekly oral dosing.
(RTTNews) - Neurocrine Biosciences, Inc. (NBIX) announced that Eiry W. Roberts will return as Chief Medical Officer, effective immediately, succeeding Sanjay Keswani, who will depart the company by mutual agreement.
(RTTNews) - Ascletis Pharma Inc. (1672.HK) reported positive Phase 1 results for ASC50 in plaque psoriasis, with the investigational oral therapy showing a 48.9% placebo-adjusted reduction in PASI score after 28 days of treatment.